Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhotic Patients (NCT05279586) | Clinical Trial Compass
UnknownEarly Phase 1
Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhotic Patients
316 participantsStarted 2022-03
Plain-language summary
The aim of this study is to compare the efficacy and safety of colistin versus lactulose for secondary prophylaxis of overt hepatic encephalopathy in patients with liver cirrhosis.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* ā¢ Age \>18 years.
* Patients with liver cirrhosis and previous history of recovery from hepatic encephalopathy.
Exclusion Criteria:
* ā¢ History of taking lactulose in past 7 days
* Patients on secondary prophylaxis for spontaneous bacterial peritonitis
* Patients on psychoactive drugs, such as antidepressants or sedatives
* Previous transjugular intrahepatic portosystemic shunts or shunt surgery
* Significant comorbid illness such as heart, respiratory, or neurological disease such as Alzheimer's disease and Parkinson's disease
* Hepatocellular carcinoma or other neoplasias that could shorten life expectancy
* Recent infection or antibiotic use within last 6 weeks
* Recent gastrointestinal bleeding in the past 6 weeks
* Renal insufficiency, myasthenia gravis.
* Hypersensitivity to colistin sulfate.
* Pregnancy or lactation
* Alcohol intake